Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7)
Public ClinicalTrials.gov record NCT05092360. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Multicenter, Open-Label, Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARTISTRY-7)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase 3, multicenter, open-label, randomized study of nemvaleukin in combination with pembrolizumab versus protocol-specific Investigator's choice chemotherapy in patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Study identification
- NCT ID
- NCT05092360
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 456 participants
Conditions and interventions
Interventions
- Nemvaleukin and Pembrolizumab Combination Biological
- Pembrolizumab Biological
- Nemvaleukin Biological
- Pegylated Liposomal Doxorubicin (PLD) Drug
- Paclitaxel Drug
- Topotecan Drug
- Gemcitabine Drug
Biological · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 10, 2022 (Actual)
- Primary completion
- Jan 8, 2025 (Actual)
- Completion
- May 8, 2025 (Actual)
- Last update posted
- Aug 28, 2025
2022 – 2025
United States locations
- U.S. sites
- 37
- U.S. states
- 21
- U.S. cities
- 34
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham | Birmingham | Alabama | 35216 | — |
| Alaska Women's Cancer Care | Anchorage | Alaska | 99508 | — |
| Arizona Oncology | Tucson | Arizona | 85711 | — |
| University of California, San Diego (UCSD)- Moores Cancer Center | La Jolla | California | 92093 | — |
| University of California, Los Angeles (UCLA) | Los Angeles | California | 90025 | — |
| Ventura County Hematology- Oncology | Oxnard | California | 93030 | — |
| University of Florida (UF) Health Cancer Center - Orlando Health | Orlando | Florida | 32808 | — |
| Sarasota Memorial Hospital | Sarasota | Florida | 34240 | — |
| Emory University | Atlanta | Georgia | 30322 | — |
| Northwestern University | Chicago | Illinois | 60611 | — |
| Rush University Medical Center | Chicago | Illinois | 60612 | — |
| Indiana University (IU) | Indianapolis | Indiana | 46202 | — |
| Mary Bird Perkins Cancer Center | Baton Rouge | Louisiana | 70809 | — |
| University of Maryland School of Medicine | Baltimore | Maryland | 21201 | — |
| Barbara Ann Karmanos Cancer Institute | Detroit | Michigan | 48224 | — |
| Trinity Health Ann Arbor Hospital | Ypsilanti | Michigan | 48197 | — |
| Astera Cancer Care | East Brunswick | New Jersey | 08816 | — |
| Rutgers Cancer Institute of New Jersey | New Brunswick | New Jersey | 08901 | — |
| University of New Mexico | Albuquerque | New Mexico | 87131 | — |
| Womens Cancer Care Associates | Albany | New York | 12208 | — |
| Westchester Medical Center | Hawthorne | New York | 105832 | — |
| NYU Langone Health | New York | New York | 10016 | — |
| David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | — |
| Vidant Medical Center | Greenville | North Carolina | 27834 | — |
| University of Cincinnati (UC) - Cancer Institute | Cincinnati | Ohio | 45219 | — |
| The Ohio State University (OSU) | Columbus | Ohio | 43026 | — |
| Mid Ohio Oncology/Hematology, Inc. dba The Mark H. Zangmeister Center | Columbus | Ohio | 43219 | — |
| Williamette Valley Cancer Institute and Research Center | Eugene | Oregon | 97401 | — |
| Providence Portland Medical Center | Portland | Oregon | 97213 | — |
| University of Pennsylvania | Philadelphia | Pennsylvania | 19014 | — |
| Avera Cancer Institute | Sioux Falls | South Dakota | 57105 | — |
| Texas Oncology - Austin Central (Balcones Dr.) | Austin | Texas | 78731 | — |
| Texas Oncology - DFWW (Bedford) | Bedford | Texas | 76022 | — |
| Texas Oncology - Fort Worth Cancer Center | Fort Worth | Texas | 76104 | — |
| Baylor College of Medicine | Houston | Texas | 77030 | — |
| University of Virginia - Emily Couric Cancer Center | Charlottesville | Virginia | 22908 | — |
| Virginia Cancer Specialists, PC (Lake Manassas Dr) | Gainesville | Virginia | 20155 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 80 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05092360, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 28, 2025 · Synced Oct 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05092360 live on ClinicalTrials.gov.